May 01, 2020
Rose
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.
from WebMD Health https://ift.tt/2yhv09Y
Subscribe to:
Post Comments (Atom)
April Health and Fitness Tips weight loss health and wellness and tips
0 comments:
Post a Comment